WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Premas Biotech
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
PharmaNewsIntelligence | March 17, 2020
Phase 1 clinical trials for a coronavirus vaccine have begun at Kaiser Permanente Washington Health Research Institute (KPWHR) has begun, according to a statement from the National Institutes of Health. The investigational vaccination, funded in part by the National Institute of Allergy and Infectious Disease, began today by administering the first immunization to a healthy adult between ages 18 and 55 years old. In total, the phase 1 clinical trial will enroll 45 adults who fit this criteria an...
Pharma Tech
Angelini Pharma | March 11, 2021
Trueblue, a main supplier of AI answers for Operational and Analytical CRM in the Life Science industry reports that Angelini Pharma, as a feature of a significant global computerized change measure, has picked AiDEA, the principal AI-Digital Cloud Pharma CRM arrangement dependent on Microsoft Dynamics 365. Angelini Pharma is a main pharmaceutical organization focused on aiding patients in the remedial zones of Central Nervous System (CNS) and Mental Health (including Pain), Rare Diseases and Co...
BioPharma Dive: | March 17, 2020
Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had delivered positive results in 2018. Eager to sell the drug to a now much wider group of patients, Amarin doubled the number of sales representatives it employs to reach out to doctors and other healt...
Fiercepharma | August 03, 2020
The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...
PHARMACY MARKET
Article
Pharmacy Market
Whitepaper
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE